Team of researchers working on drug discovery

Active Clinical Trials

Cell close up over blue background

Advancing Regenerative Therapies that Reverse Chronic Disease

We are developing an innovative cell therapy pipeline with the potential to redefine standards of care across a range of conditions where there is an urgent medical need.  We are applying our proprietary CD34+ cell technology to potentially treat a number of conditions caused by underlying ischemic injury, including but not limited to, Coronary Microvascular Dysfunction (CMD), Critical Limb Ischemia (CLI) and Diabetic Kidney Disease (DKD).

Active Clinical Trials

The FREEDOM Trial: Coronary Microvascular Dysfunction (CMD)

Status: Actively Recruiting 

A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of XOWNA® (CLBS16) in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease. 

This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of XOWNA® or placebo.

Learn more about the FREEDOM trial on (Identifier: NCT04614467) or by visiting

HONEDRA(CLBS12): Critical Limb Ischemia (CLI)

Status: Actively Recruiting 

A Phase 2 study  in Japan evaluating an autologous CD34+ cell therapy (HONEDRA for the treatment of critical limb ischemia, or CLI).